COSMOCOL PLAIN POWDER FOR ORAL SOLUTION  
DISDOCCOL ORANGE LEMON AND LIME FLAVOUR POWDER  
FOR ORAL SOLUTION  

(sodium chloride, sodium hydrogen carbonate, potassium chloride, macrogol 3350)  

PL 36170/0001 and Pl 36170/0002  

UKPAR  

**TABLE OF CONTENTS**  

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lay Summary</td>
<td>2</td>
</tr>
<tr>
<td>Scientific discussion</td>
<td>4</td>
</tr>
<tr>
<td>Steps taken for assessment</td>
<td>10</td>
</tr>
<tr>
<td>Steps taken after authorisation – summary</td>
<td>11</td>
</tr>
<tr>
<td>Summary of Product Characteristics</td>
<td>12</td>
</tr>
<tr>
<td>Product Information Leaflet</td>
<td>12</td>
</tr>
<tr>
<td>Labelling</td>
<td>13</td>
</tr>
</tbody>
</table>
LAY SUMMARY
CosmoCol Plain Powder for Oral Solution
DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution
(sodium chloride, sodium hydrogen carbonate, potassium chloride, macrocol 3350)

This is a summary of the public assessment report (PAR) for CosmoCol Plain Powder for Oral Solution (PL 36170/0001) and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution (PL 36170/0002). It explains how CosmoCol Plain Powder for Oral Solution and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution were assessed and their authorisations recommended, as well as their conditions of use. It is not intended to provide practical advice on how to use CosmoCol Plain Powder for Oral Solution and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution.

For practical information about using CosmoCol Plain Powder for Oral Solution and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution, patients should read the Patient Information Leaflets or contact their doctor or pharmacist.

What are CosmoCol Plain Powder for Oral Solution and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution and what are they used for?

CosmoCol Plain Powder for Oral Solution and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution contain the active substances sodium chloride, sodium hydrogen carbonate, potassium chloride and macrocol 3350. These medicines are laxatives prescribed for the treatment of long-term constipation.

These medicines are identical to Macroherm Powder for Oral Solution (PL 17740/0008), which was authorised in the UK to Hermes Arzneimittel GmbH on 12 October 2010. Hermes Arzneimittel GmbH has agreed that scientific data presented for Macroherm Powder for Oral Solution (PL 17740/0008) can be used for these applications for CosmoCol Plain Powder for Oral Solution and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution.

How do CosmoCol Plain Powder for Oral Solution and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution work?

CosmoCol Plain Powder for Oral Solution and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution contain the active ingredients sodium chloride, sodium hydrogen carbonate, potassium chloride and macrocol 3350. The macrocol 3350 in these medicines works by making the faeces softer and easier to pass, giving relief from constipation. The salts (electrolytes) help to maintain the body’s normal levels of sodium chloride, sodium hydrogen carbonate, potassium chloride and water, whilst treatment for constipation is in progress.

How are CosmoCol Plain Powder for Oral Solution and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution used?

CosmoCol Plain Powder for Oral Solution and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution are for oral use only. These medicines can be obtained without a prescription from a pharmacy. The recommended dose for constipation in adults, children (aged 12 years and above) and the elderly is one sachet taken one to three times daily. The contents of each sachet must be poured into a glass and dissolved in about 125 ml or a quarter pint of water. As for all laxatives, prolonged use is not usually recommended. Please read Section 3 of the Patient Information Leaflets.
for detailed information on dosing recommendations, the route of administration and the duration of treatment.

**What benefits of CosmoCol Plain Powder for Oral Solution and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution have been shown in studies?**

These applications for CosmoCol Plain Powder for Oral Solution and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution are identical to the previously granted application for Macroherm Powder for Oral Solution (PL 17740/0008; Hermes Arzneimittel GmbH). The applicant (HWI ANALYTIK GmbH) referred to data provided by Hermes Arzneimittel GmbH for the grant of these applications as the basis for the grant of an identical licence.

**What are the possible side effects of CosmoCol Plain Powder for Oral Solution and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution?**

Because CosmoCol Plain Powder for Oral Solution and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution are generic medicines and both are identical to the previously granted application for Macroherm Powder for Oral Solution (PL 17740/0008; Hermes Arzneimittel GmbH), the benefits and possible side effects are taken as being the same as the previously granted application.

**Why are CosmoCol Plain Powder for Oral Solution and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution approved?**

No new or unexpected safety concerns arose from these applications. It was, therefore, considered that the benefits of these medicines outweigh their risks. Therefore, the grant of Marketing Authorisations for these products was recommended.

**What measures are being taken to ensure the safe and effective use of CosmoCol Plain Powder for Oral Solution and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution?**

A risk management plan has been developed to ensure that CosmoCol Plain Powder for Oral Solution and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution are used as safely as possible. Based on this plan, safety information has been included in the Summaries of Product Characteristics and the Patient Information Leaflets for CosmoCol Plain Powder for Oral Solution and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution, including the appropriate precautions to be followed by healthcare professionals and patients.

**Other information about CosmoCol Plain Powder for Oral Solution and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution**

Marketing Authorisations for these products were granted on 09 July 2014 to HWI ANALYTIK GmbH. For more information about treatment with CosmoCol Plain Powder for Oral Solution and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution, read the Patient Information Leaflets, or contact your doctor or pharmacist.

This summary was last updated in September 2014.

The full PAR for CosmoCol Plain Powder for Oral Solution and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution follow this summary.
COSMOCOL PLAIN POWDER FOR ORAL SOLUTION
DISDOCCOL ORANGE LEMON AND LIME FLAVOUR POWDER
FOR ORAL SOLUTION

(PL 36170/0001 and PL 36170/0002)

SCIENTIFIC DISCUSSION

TABLE OF CONTENTS

Introduction Page 5
Pharmaceutical assessment Page 6
Non-clinical assessment Page 8
Clinical assessment Page 8
Overall conclusion and benefit/risk assessment Page 9
INTRODUCTION

Based on the review of the data on quality, safety and efficacy, the UK granted Marketing Authorisations for the medicinal products CosmoCol Plain Powder for Oral Solution (PL 36170/0001) and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution (PL 36170/0002) on 09 July 2014 to HWI ANALYTIK GmbH.

These applications for CosmoCol Plain Powder for Oral Solution and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution were submitted as abridged simple applications according to Article 10c of Directive 2001/83/EC, as amended, cross-referring to Macroherm Powder for Oral Solution, which was granted a licence to Hermes Arzneimittel GmbH on 12 October 2010 (PL 17740/0008).

CosmoCol Plain Powder for Oral Solution and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution can be obtained without a prescription from a pharmacy (legal status P) and are indicated for the treatment of chronic constipation.

CosmoCol Plain Powder for Oral Solution and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution contain the active ingredients sodium chloride, sodium hydrogen carbonate, potassium chloride and macrogol 3350. These products are osmotically acting laxatives. Macrogol 3350 induces a laxative effect through its osmotic action in the gut. Macrogol 3350 increases the stool volume, which in turn causes colon motility via neuromuscular pathways. The physiological consequence is an improved propulsive colonic transportation of the softened stools and a facilitation of the defaecation. Electrolytes combined with macrogol 3350 are exchanged across the intestinal barrier (mucosa) with serum electrolytes, and excreted in faecal water without net gain or loss of sodium, potassium and water.
PHARMACEUTICAL ASSESSMENT

LICENCE NO:  PL 36170/0001-0002

PROPRIETARY NAME(S): CosmoCol Plain Powder for Oral Solution and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution

ACTIVE(S): sodium chloride, sodium hydrogen carbonate, potassium chloride, macrogol 3350

COMPANY NAME: HWI ANALYTIK GmbH

E.C. ARTICLE: Article 10c of Directive 2001/83/EC, as amended

LEGAL STATUS: P

1. INTRODUCTION

These are simple, piggyback applications for CosmoCol Plain Powder for Oral Solution and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution submitted under Article 10c of Directive 2001/83/EC, as amended. The proposed Marketing Authorisation Holder is HWI ANALYTIK GmbH, Rheinzaberner Strasse 8, D-76761 Ruelzheim, Germany.

These applications cross-refer to Macroherm Powder for Oral Solution (PL 17740/0008), which was granted a licence to Hermes Arzneimittel GmbH on 12 October 2010.

The current applications are considered valid.

2. MARKETING AUTHORISATION APPLICATION FORM

2.1 NAME(S)

The proposed product names are CosmoCol Plain Powder for Oral Solution and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution. These products have been named in line with current requirements.

2.2 Strength, pharmaceutical form, route of administration, container and pack sizes

Each sachet contains the following quantitative composition of active ingredients:

- Sodium chloride 0.3507g
- Sodium hydrogen carbonate 0.1785g
- Potassium chloride 0.0466g
- Macrogol 3350 13.125g

The content of electrolyte ions per sachet following reconstitution in 125 ml of water is equivalent to:

- Sodium 65 mmol/l
- Chloride 53 mmol/l
- Hydrogen carbonate (bicarbonate) 17 mmol/l
- Potassium 5 mmol/l

Each sachet is composed of paper, ethylene-methacrylic acid co-polymer and aluminium. These are packed in cartons of 2, 6, 8, 10, 20, 30, 50, 60 (2x30) and 100 (2x50) sachets.

The Marketing Authorisation Holder has stated that not all pack sizes are intended for marketing. However, they have committed to providing the MHRA with the mock-ups for any pack size before marketing.

The proposed shelf-life for the sachet (36 months) and the reconstituted solution (24 hours), and the storage conditions for the sachet (Do not store above 25 °C) and the reconstituted solution (Store
covered in a refrigerator [2°C to 8°C]) are consistent with the details registered for the cross-reference product.

2.3 Legal status
On approval, these products will be available without a prescription from a pharmacy (legal status P).

2.4 Marketing authorisation holder/Contact Persons/Company
HWI ANALYTIK GmbH, Rheinzaberner Strasse 8, D-76761 Ruelzheim, Germany.

The QP responsible for pharmacovigilance is stated and their CV is included.

2.5 Manufacturers
The proposed manufacturing sites are consistent with those registered for the cross-reference product and evidence of Good Manufacturing Practice (GMP) compliance has been provided.

2.6 Qualitative and quantitative composition
The proposed composition is consistent with the details registered for the cross-reference product.

2.7 Manufacturing process
The proposed manufacturing process is consistent with the details registered for the cross-reference product and the maximum batch sizes are stated.

2.8 Finished product/shelf-life specification
The proposed finished product specification is in line with the details registered for the cross-reference product.

2.9 Drug substance specification
The proposed drug substance specifications are consistent with the details registered for the cross-reference product.

2.10 TSE Compliance
No materials of animal or human origin are included in this product. This is consistent with the cross-reference product.

3. EXPERT REPORTS
The applicant has included detailed expert reports in Module 2 of the applications. Signed declarations and copies of the experts’ CVs are enclosed in Module 1.4 for the quality, non-clinical and clinical experts. All are considered to have sufficient experience for their responsibilities.

4. PRODUCT NAME & APPEARANCE
See 2.1 for details of the proposed product names. The appearance of the products is identical to the cross-reference product.

5. SUMMARY OF PRODUCT CHARACTERISTICS (SmPC)
The proposed SmPCs are consistent with the details registered for the cross-reference product.
6. PATIENT INFORMATION LEAFLET (PIL)/CARTON

The patient information leaflets have been prepared in line with the details registered for the cross-reference product.

Labelling
The proposed artworks are comparable to the artwork registered for the cross-reference product and comply with statutory requirements. In line with current legislation, the applicant has also specified that the name of the product in Braille will be included on the outer packaging.

7. CONCLUSIONS
The data submitted with these applications are acceptable. From a quality perspective, Marketing Authorisations may be granted.

NON-CLINICAL ASSESSMENT

No new non-clinical data have been supplied with these applications and none are required for applications of this type.

CLINICAL ASSESSMENT

No new clinical data have been supplied with these applications and none are required for applications of this type.
OVERALL CONCLUSION AND BENEFIT/RISK ASSESSMENT

QUALITY
The important quality characteristics of CosmoCol Plain Powder for Oral Solution and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution are identical to those of the already granted reference product. There are no outstanding quality issues that would have a negative impact on the benefit/risk balance.

NON-CLINICAL
No new non-clinical data were submitted and none are required for applications of this type.

CLINICAL PHARMACOLOGY/EFFICACY
No new clinical pharmacology/efficacy data have been submitted with these applications and none are required for applications of this type.

SAFETY
No new safety data have been submitted and none are required for applications of this type.

No new or unexpected safety concerns arose from these applications.

The SmPCs, PILs and labelling are satisfactory.

Pharmacovigilance System and Risk Management Plan
The Pharmacovigilance System, as described by the applicant, fulfils the requirements and provides adequate evidence that the applicant has the services of a qualified person responsible for pharmacovigilance, and has the necessary means for the notification of any adverse reaction suspected of occurring either in the Community or in a third country.

A risk management plan has been developed to ensure that CosmoCol Plain Powder for Oral Solution and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution are used as safely as possible. Based on this plan, safety information has been included in the Summaries of Product Characteristics and the Patient Information Leaflets for CosmoCol Plain Powder for Oral Solution, and DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution, including the appropriate precautions to be followed by healthcare professionals and patients.

BENEFIT-RISK ASSESSMENT
The quality of the products is acceptable, and no new non-clinical or clinical safety concerns have been identified. Extensive clinical experience with sodium chloride, sodium hydrogen carbonate, potassium chloride and macrogol 3350 is considered to have demonstrated the therapeutic value of the products. The benefit/risk is, therefore, considered to be positive.
COSMOCOL PLAIN POWDER FOR ORAL SOLUTION
DISDOCCOL ORANGE LEMON AND LIME FLAVOUR POWDER FOR ORAL SOLUTION

(PL 36170/0001 and PL 36170/0002)

**STEPS TAKEN FOR ASSESMENT**

<table>
<thead>
<tr>
<th></th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>The MHRA received the Marketing Authorisation applications on 22 October 2013</td>
</tr>
<tr>
<td>2</td>
<td>Following standard checks and communication with the applicant, the MHRA considered the applications valid on 31 October 2013</td>
</tr>
<tr>
<td>3</td>
<td>Following assessment of the applications, the MHRA requested further information relating to both applications on 30 January 2014</td>
</tr>
<tr>
<td>4</td>
<td>The applicant responded to the MHRA’s requests, providing further information on 02 April 2014 (PL 36170/0001) and 22 April 2014 (PL 36170/0002)</td>
</tr>
<tr>
<td>5</td>
<td>The applications were determined on 09 July 2014</td>
</tr>
</tbody>
</table>
COSMOCOL PLAIN POWDER FOR ORAL SOLUTION
DISDOCCOL ORANGE LEMON AND LIME FLAVOUR POWDER
FOR ORAL SOLUTION

(PL 36170/0001 and PL 36170/0002)

STEPS TAKEN AFTER AUTHORISATION - SUMMARY

<table>
<thead>
<tr>
<th>Date submitted</th>
<th>Application type</th>
<th>Scope</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


Summaries of Product Characteristics and Patient Information Leaflets
The current approved UK versions of the Summaries of Product Characteristics (SmPCs) and Patient Information Leaflets (PILs) for these products are available on the MHRA website.
CosmoCol Plain Powder for Oral Solution

For oral use.
Read the package leaflet before use.
Keep out of the sight and reach of children.

Unopened sachets should not be stored above 25°C.
Reconstituted CosmoCol Plain solution can be covered and stored in the refrigerator (2°C to 8°C) and should be used within 24 hours.
After 24 hours, any unused solution should be discarded.
For chronic constipation.

Dosage:
Adults, adolescents and elderly: 1-3 sachets per day, according to individual response.
Dissolve the contents of one sachet in 125 ml of water then drink it.

CosmoCol Plain Powder for Oral Solution

For oral use.
Read the package leaflet before use.
Keep out of the sight and reach of children.

Unopened sachets should not be stored above 25°C.
Reconstituted CosmoCol Plain solution can be covered and stored in the refrigerator (2°C to 8°C) and should be used within 24 hours.
After 24 hours, any unused solution should be discarded.
For chronic constipation.

Dosage:
Adults, adolescents and elderly: 1-3 sachets per day, according to individual response.
Dissolve the contents of one sachet in 125 ml of water then drink it.
UKPAR CosmoCol Plain Powder for Oral Solution

DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution

PL 36170/0001-0002

For oral use. Read the package leaflet before use.

Keep out of the sight and reach of children.

Unopened sachets should not be stored above 25 °C.

Reconstituted DisDocCol Orange Lemon & Lime Flavour solution can be covered and stored in the refrigerator (2 °C to 8 °C) and should be used within 24 hours.

After 24 hours, any unused solution should be discarded.

For chronic constipation:

Dosage:

Adults, adolescents and elderly: 1-3 sachets per day, according to individual response.

Dissolve the contents of one sachet in 125 ml of water then drink it.
UKPAR CosmoCol Plain Powder for Oral Solution
DisDocCol Orange Lemon and Lime Flavour Powder for Oral Solution

Each sachet contains:
- Macrogol 3350 (Polyethylene glycol 3350) 13.125 g
- Sodium chloride 0.3507 g
- Sodium hydrogen carbonate 0.1785 g
- Potassium chloride 0.0466 g

On reconstitution in 125 ml of water, each sachet provides:
- Sodium 65 mmol/l
- Chloride 55 mmol/l
- Hydrogen carbonate 17 mmol/l
- Potassium 5 mmol/l

Contains sorbitol (E420).
See leaflet for further information.

PL 36170/0002

DisDocCol is a registered trademark.

Batch: EXP: